2 July 2024

Howe Street Reporter Title

Tag: bioasis technologies

  • Bioasis Technologies (BTI.V): To Invest or Not?

    Bioasis Technologies (BTI.V): To Invest or Not?

    For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain. One reason for that is the blood-brain barrier. That’s why in this episode, we take a look at Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF). Their proprietary…

  • Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)

    Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)

    Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer’s disease, Lewy Body Dementia and Parkinson’s. In short, Bioasis’ final frontier solution could very well revolutionize medical…

  • Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal

    Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal

    Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according to a press release. The terms of the agreement give Bioasis the ability to issue convertible securities up to $10 million with proceeds going to general…

  • Bioasis Technologies (BTI.V) and the painful price of private sector science

    Bioasis Technologies (BTI.V) and the painful price of private sector science

    Science isn’t cheap. Overhead for scientific based companies is usually sky high for a reason. It’s not just keeping the lights on, or making sure everyone from the CEO to the janitorial staff get paid on time, although that’s part of it. It’s revolving costs in equipment, other forms of capital—like human capital—the average science…